Answer
Predominantly cholestatic liver injury, including hepatic failure with fatal outcomes, has been reported during tigecycline treatment; underlying conditions or concomitant medicines may cause hepatic failure, but a possible contribution from tigecycline should be considered.
Sources for this answer
- Tygacil 50mg powder for solution for infusion / Tigecycline 50 mg powder for solution for infusionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 42Document updated
Sources checked